8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Feb 10, 2006)

Filed February 10, 2006For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on February 10, 2006, to disclose its forward-looking financial expectations. The report primarily serves to incorporate by reference a press release issued on the same date, which details the company's projections for the upcoming years. This includes anticipated full-year diluted earnings per share (EPS) for 2006, presented on both an adjusted and a Generally Accepted Accounting Principles (GAAP) basis. Investors should pay close attention to these forward-looking statements as they provide insights into the company's anticipated financial performance and strategic outlook. This filing is significant because it offers management's guidance on key financial metrics, allowing investors to assess the company's potential trajectory and make informed investment decisions. The inclusion of both adjusted and GAAP EPS figures is standard practice, offering different perspectives on the company's underlying operational profitability and its reported results. The market will be closely watching these figures against actual performance in subsequent periods.

Key Highlights

  • 1Pfizer Inc. filed an 8-K report on February 10, 2006.
  • 2The filing incorporates a press release dated February 10, 2006, by reference.
  • 3The press release contains Pfizer's expectations and forecasts for the next few years.
  • 4Key financial guidance provided includes full-year 2006 diluted earnings per share (EPS) expectations.
  • 5EPS figures are presented on both an adjusted basis and a GAAP basis.
  • 6The filing is primarily an 'Other Events' disclosure (Item 8.01).
  • 7Exhibit 99 contains the full text of the press release.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally disclose Pfizer Inc.'s financial expectations and forecasts for the upcoming years, as detailed in a press release issued on the same day. This includes guidance on their projected earnings per share for the full year 2006.

The press release, incorporated by reference, provides Pfizer's expectations for the next few years, with a specific focus on forecasts for full-year 2006 diluted earnings per share (EPS). These EPS figures are expected to be presented on both an adjusted basis and a GAAP basis.

This filing is important for investors as it provides management's forward-looking guidance on key financial metrics like EPS. This information helps investors assess the company's anticipated performance, understand its strategic outlook, and make more informed investment decisions by comparing these projections with actual results in the future.

While the filing itself doesn't define 'adjusted basis,' in financial reporting, it typically refers to earnings per share that exclude certain non-recurring or extraordinary items, such as restructuring charges, acquisition-related costs, or significant one-time gains or losses. This aims to provide a clearer view of the company's ongoing operational performance.